Changes in acromegaly treatment over four decades in Spain: Analysis of the Spanish Acromegaly Registry (REA)

Pituitary

Volumn 16, Issue 1, 2013, Pages 115-121

  Sesmilo, Gemma ^a   Gaztambide, Sonia ^b   Venegas, Eva ^c   Picó, Antonio ^d   Del Pozo, Carlos ^e   Blanco, Concepción ^f   Torres, Elena ^g   Álvarez Escolà, Cristina ^h   Fajardo, Carmen ⁱ   García, Rogelio ^j   Cámara, Rosa ^k   Bernabeu, Ignacio ^l   Soto, Alfonso ^c   Villabona, Carles ^m   Serraclara, Alicia ⁿ   Halperin, Irene ^o   Alcázar, Victoria ^p   Palomera, Elisabet ^q   Webb, Susan M ^r  

^a INSTITUT UNIVERSITARI DEXEUS   (Spain)

^b HOSPITAL DE CRUCES   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^e HOSPITAL MÚTUA DE TERRASSA   (Spain)

^f HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^g HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

ⁱ HOSPITAL DE LA RIBERA   (Spain)

^j HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^k HOSPITAL UNIVERSITARIO LA FE   (Spain)

^l UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^m HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

ⁿ HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^o HOSPITAL CLÍNIC   (Spain)

^p HOSPITAL SEVERO OCHOA   (Spain)

^q HOSPITAL DE MATARÓ   (Spain)

^r UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

more..

Author keywords

Acromegaly; Registry; Treatment

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; OCTREOTIDE; PEGVISOMANT; SOMATOSTATIN RECEPTOR;

ACROMEGALY; ADENOMA; ADULT; ARTICLE; CANCER RADIOTHERAPY; DISEASE CONTROL; FEMALE; HUMAN; HYPOPHYSIS ADENOMA; MAJOR CLINICAL STUDY; MALE; MICROADENOMA; PRIORITY JOURNAL; REGISTER; SPAIN; SURGICAL TECHNIQUE; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 84873704038     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-012-0384-x     Document Type: Article

References (23)

1. Etxabe J, Gaztambide S, Latorre P, Vazquez JA (1993) Acromegaly: an epidemiological study. J Endocrinol Invest 16:181-187
2. Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M, Gilabert M (2004) Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 151:439-446
3. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A (2009) Guidelines for acromegaly management: an Update. J Clin Endocrinol Metab 94:1509-1517
4. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF (2000) Davis RJ.T reatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171-1177
5. Johnson MR, Chowdrey HS, Thomas F, Grint C, Lightman SL (1994) Pharmacokinetics and efficacy of the long-acting somatostatin analogue somatuline in acromegaly. Eur J Endocrinol 130:229-234
6. Hunter SJ, Shaw JA, Lee KO, Wood PJ, Atkinson AB, Bevan JS (1999) Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion. Clin Endocrinol 50:245-251
7. Caron P, Bex M, Cullen DR, Feldt-Rasmussen U, Pico Alfonso AM, Pynka S, Racz K, Schopohl J, Tabarin A, Valimaki MJ (2004) One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol 60:734-740
8. Lucas T, Spanish-Portuguese Multicentre Autogel Study Group on Acromegaly (2006) Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. Clin Endocrinol (Oxf) 65(3):320-326
9. ® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR. Exp Clin Endocrinol Diabetes 119(3):156-162
10. Biermasz NR, van den Oever NC, Frölich M, Arias AM, Smit JW, Romijn JA, Roelfsema F (2003) Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval. Clin Endocrinol (Oxf) 58:288-295
11. Giustina A, Bonadonna S, Bugari G, Colao A, Cozzi R, Cannavo S, de Marinis L (2009) Degli Uberti E, Bogazzi F, Mazziotti G, Minuto F, Montini M, Ghigo E. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol 161:331-338
12. Ben-Shlomo A, Melmed S (2007) Pasireotide - a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease. IDrugs 10:885-895
13. Frank G, Pasquini E (2006) Endoscopic cavernous sinus surgery with special reference to pituitary adenomas. In: Laws ER, Sheehan JP (eds) Pituitary surgery - a modern approach. Karger, Basel, pp 64-82
14. Fahlbusch R, Keller B, Ganslandt O, Kreutzer J, Nimsky C (2005) Transsphenoidal surgery in acromegaly investigated by intraoperative high-field magnetic resonance imaging. Eur J Endocrinol 153:239-248
15. Bex M, Abs R, T'Sjoen G, Mockel J, Velkeniers B, Muermans K, Maiter D (2007) AcroBel - the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects. Eur J Endocrinol 157(4):399-409
16. Jaquet P, Cortet-Rudelli Ch, Sassolas G, Morange-Ramos I, Chanson P, Brue T, Andrieu JM, Beckers A, Bertherat J, Borson-Chazot F, Brassier G, Caron P, Cogne M, Cottier JP, Delemer B, Dufour H, Enjalbert A, Figarella-Branger D, Gaillard R, Gueydan M, Jan M, Kuhn JM, Raingeard I, Regis J, Roger P, Rohmer V, Sadoul JL, Saveanu A, Tabarin A, Travers N, French Acromegly Registry (2003) Therapeutic strategies in somatotroph adenomas with extrasellar extension: role of the medical approach, a consensus study of the French Acromegaly Registry. Ann Endocrinol (Paris) 64(6):434-441
17. Colao A, Ferone D, Cappabianca P, del Basso De Caro ML, Marzullo P, Monticelli A, Alfieri A, Merola B, Cali A, de Divitiis E, Lombardi G (1997) Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 82:3308-3314
18. Losa M, Mortini P, Urbaz L, Ribotto P, Castrignano T, Giovanelli M (2006) Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates. J Neurosurg 104:899-906
19. Petersenn S, Buchfelder M, Reincke M, Strasburger CM, Franz H, Lohmann R, Quabbe HJ, Participants of the German Acromegaly Register (2008) Results of surgical and somatostatin analog therapies and their combination in acromegaly: a retrospective analysis of the German acromegaly register. Eur J Endocrinol 159(5):525-532
20. Fieffe S, Morange I, Petrossians P, Chanson P, Rohmer V, Cortet C, Borson-Chazot F, Brue T, The French Acromegaly Registry (2011) Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. Eur J Endocrinol 164(6):877-884
21. Biermasz NR, Roelfsema F, Pereira AM, Romijn JA (2009) Cost-effectiveness of lanreotide autogel in treatment algorithms of acromegaly. Expert Rev Pharmacoecon Outcomes Res 9:223-234
22. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Acromegaly Consensus Group (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:1509-1517
23. Mullan K, Sanabria C, Abram WP, McConnell EM, Courtney HC, Hunter SJ, McCance DR, Leslie H, Sheridan B, Atkinson AB (2009) Long term effect of external pituitary irradiation on IGF1 levels in patients with acromegaly free of adjunctive treatment. Eur J Endocrinol 161:547-551